Category Archives: Immunology

Duke health experts call for patience, testing, improved federal coordination in pandemic battle – ncpolicywatch.com

Image: Adobe Stock

Sudden reopening would jeopardize progress made thus far

This is Day 50. It feels like Day 500.

A new coronavirus, which technically isnt even alive, has outwitted us. The COVID-19 pandemic has paralyzed the state and the nation, vanquished our economy and killed 40,000 people in the U.S. including 235 in North Carolina and another 131,000 worldwide, all of whom were loved by someone.

How do we gain the upper hand over an invisible pathogen that moves stealthily and with no regard for its target?

On April 21, three doctors affiliated with Duke University discussed the prospects for reopening the nation, the inconsistent federal response, and clarified the nuances of testing, both for coronavirus antibodies and active COVID-19 infections. The conversation was held via videoconference with the media.

Dr. Michael Dee Gunn is an immunology professor at the Duke University School of Medicine. From a medical perspective, people advocating a premature opening of the economy, Gunn said, are advocating that every person in this country become infected with coronavirus.

Reopeners are primarily far-right conservatives inspired by the likes of Infowarss Alex Jones and other discredited conspiracy theorists. They have staged numerous demonstrations nationwide to protest not only states stay-at-home orders but also science.

Yet the publics impatience is expected. No one has shown them the light at the end of the tunnel, Gunn said. It would be very beneficial if at the federal level someone said, This is the schedule were on, and give people an expectation to work with. As it is now, [the message] changes every day. No wonder everyone is frustrated.

The Trump administration has whipsawed the public with conflicting messages that are driven by politics, not science. Even though he had been briefed to the contrary months earlier, President Trump said in early March that the virus was no worse than the flu, and would soon disappear. Instead of disappearing, over the next six weeks 40,000 people in the U.S. died and in the hardest-hit areas, the entire medical system was overwhelmed with cases.

Despite the presidents assurances that plenty of testing and medical equipment were available, there have been severe shortages of both, resulting in a Lord of the Flies-like competition among states for ventilators, masks and protective gowns.

The sideshow continued in late March, when Trump said the country would open by Easter. Then under pressure from public health officials, Trump postponed the date until May 1, which experts said was still too soon. Shortly afterward, Trump said he had total authority to reopen the country, an assertion that has no constitutional basis. Then he backtracked, and put the onus on state governors to decide how to lift their stay-at-home orders.

But Trump soon undermined the states efforts; within a day via Twitter he incited demonstrations against the governors in several states where stay-at-home orders are in place: Minnesota, Michigan and Virginia.

Like a virus, those demonstrations spread to other states, including North Carolina. U.S. Rep. Dan Bishop of the ninth congressional district and State Sen. Vickie Sawyer, both Republicans, are among the elected officials who attended the protests. Gov. Roy Cooper has said as long as protesters remain six feet apart the standard recommendation for social distancing the demonstrations are allowed.

Dr. Thomas Denny, chief operating officer of the Duke Human Vaccine Institute, said the country should be reopened gradually or risk higher rates of infection and death. Im concerned that in this rush were forgetting everything weve learned, Denny said.

I know there are a lot of people who have lost their jobs. They may be motivated by that, and I understand, but we need to address the economics on a national level and take this slower. There could be rings of containment and rings of loosening, based on health data, Denny said.

While the reopeners are seizing their moment in the spotlight, most people in America are quietly and nervously trying to avoid becoming infected. A recent Washington Post-University of Maryland poll found that of 1,013 people surveyed, with 57% saying they are very or somewhat worried about becoming infected and seriously ill from the coronavirus. Multiple polls have found that Americans are more worried about reopening the economy too quickly than too slowly.

What the federal government needs to do right now is to come up with a coherent plan, Gunn said. The American people are willing to sacrifice for the common good. The government needs to say, Were asking you to buy into it. Thats who were going to get control of this virus.

Testing free-for-all must be reined in, better coordinated

Gaining control of the coronavirus will require widespread testing: One type to determine if someone has an active infection and should be treated and isolated; another to detect antibodies in the blood, which indicate the person has been infected at some point in the past.

The Centers for Disease Control and Prevention initially shipped thousands of flawed test kits that had been made in a contaminated lab. Subsequently the FDA fast-tracked millions of antibody testing kits some that had never been verified to county health departments, only to learn later that many of them were faulty.

Its been a free-for-all, Gunn said. Every company that could put out a test, did. Theres not been the quality control that this needs. We need a national coordination.

Test kits, enzymes, chemicals, reagents, protective gear for health care workers administering the tests: All of these must be manufactured en masse, quickly but precisely.

Its a complicated test, Gunn said. Its not instant. We need to develop tests that are sensitive enough so that we have rapid results like pregnancy tests.

Once reliable antibody tests are available, first responders and health workers should be the first to receive them, Denny said. Hopefully if we have another surge well have a better understanding of the risk those individuals have.

Its nearly certain that even in states where the number of reported cases is declining, there will be another surge in the fall or sooner, depending on how quickly the stay-at-home orders are lifted.

A robust tracking system, including painstakingly tracing an infected persons contacts could help contain smaller outbreaks, Gunn said. Its like a forest fire. Once its under control, its a matter of managing the hotspots.

And there will be hotspots. Since the virus is new, scientists dont yet fully understand how it behaves. For example, simply having antibodies for the virus doesnt mean you are immune to it, Gunn said.

And after people recover, its unclear who is immune and how long people shed the virus. What risk that poses is not well understood, said Dr. Chris Woods, co-director of the Center for Global Health at Duke University and chief of the infectious diseases division Durham VA Medical Center. Were still learning a lot about how its transmitted, and whether or not there is a change in the virus that makes it more transmissible or more or less virulent over time.

An estimated 7,000 people in North Carolina have tested positive for COVID-19. That is likely an undercount because of the testing shortage. Moreover, many people with mild or moderate symptoms dont go to the doctor so their cases arent counted. But even if 1 million North Carolinians have had the disease in some form, thats still only 10% of the state population. That means 90% of North Carolinians would be vulnerable.

We need to understand the background rate of immunity, Woods said. Without the benefit of herd immunity which occurs when large numbers of people have become immune to the disease and provide indirect protection for people who havent yet had it we would expect periodic outbreaks of disease but we would have public health tools to contain it.

While the federal government, especially the CDC, which has been nearly invisible throughout the crisis, needs to provide funding and technical support, the burden of containment will likely fall to the states and county health departments.

It will be costly and it will take a lot of people to execute these plans, Denny said. The local health departments are very important to identify who are most at risk like low-income people, who typically see more health problems and then work out a plan. Its going to take time.

This story has been corrected to show that 7,000 people in North Carolina have tested positive for the coronavirus.

Continue reading here:
Duke health experts call for patience, testing, improved federal coordination in pandemic battle - ncpolicywatch.com

Meet the North Smithfield native working on a cure for coronavirus – Valley Breeze

4/22/2020

Timothy Sheahan, a research scientist with a Ph.D. in microbiology and immunology, is one of only a handful of scientists in the country testing cures for the coronavirus. Here he is pictured in the lab at the Gillings School of Global Public Health at UNC-Chapel Hill.

NORTH SMITHFIELD When Timothy Sheahan was working his first job as a dishwasher at Coffee & Cream, one of his coworkers gave him the nickname professor. He wasnt an academic star at Mount Saint Charles Academy, where he graduated in 1994, he didnt take AP biology but he enjoyed science and would go on to study it at the University of New Hampshire.

His name was Danny, and he ran the drive-thru, Sheahan recalled during a phone interview last week. And because I was a nerd, he would call me professor. And I just realized that now Im a professor, and its ironic.

Sheahan isnt just a professor. Hes also a research scientist at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. The lab he works in specializes in coronaviruses and is one of only a handful of labs around the country working on a cure for COVID-19.

Were tasked with being the front line of evaluating new things that could save lives in the U.S. and across the globe, he said Its a position that people like me are rarely in, especially under this time scale where things need to be done as soon as possible, and you do it because thats whats happening now.

Sheahan is no stranger to coronaviruses, the family of viruses that includes the strain that causes COVID-19. After graduating from the University of New Hampshire, he worked in a lab at Harvard Medical School and completed his PhD work at UNC Chapel Hill, later returning as a faculty member. Much of his work has focused on developing treatments to existing coronaviruses, including the ones that caused the SARS outbreak in China in 2002 and the MERS outbreak in the Middle East in 2012.

When COVID-19 began to emerge late last year, hed been experimenting with remdesivir, a drug originally developed by the pharmaceutical company Gilead to treat Ebola, to see if it would work against MERS.

But then this new coronavirus comes along, and we start studying it, he said. We had a pretty good feeling that remdesivir would work in a lab against this virus, and that turns out to be true.

Remdesivir is now one of the leading drugs being studied in the U.S. as a possible treatment to COVID-19, but theres still a lot of work to do. Sheahan and his colleagues accomplish that work in their lab in full safety gear, including scrubs, hazmat suits, gloves, booties and enclosed hoods that receive clean air from battery-powered respirators. Everyone who works at the lab has an FBI background check and does their work in biosafety cabinets to prevent any escape of the virus.

Despite the deadly viruses around him, Sheahan said the lab is a safe and comforting place to work, especially at a time when hes more likely to catch COVID-19 walking into the grocery store than cocooned beneath layers of safety equipment.

At the same time as hes battling a worldwide disease, hes also juggling the pressures of being a parent with two young kids at home. A typical day involves waking up and spending the morning helping his kids with schoolwork before heading into the lab around noon. Then its back home for dinner and some brief family time before working from home until midnight. He works through weekends, a schedule that makes him feel more like a PhD student than an assistant professor in his 40s.

When I get home and read two chapters of Harry Potter to my kids before bed, that is a breath of fresh air, he said.

Sheahan said he tries to talk about things other than coronavirus when hes at home, but its difficult when everyone, including his parents, Rudy and Helene Sheahan in North Smithfield, has suddenly become well versed in what he does. Finding himself at the center of the worlds response, he said, has been weird, and something he never wouldve predicted when he was 15.

At the time, he was more interested in recording music, and said one of his highlights at Mount Saint Charles was when his English teacher, John Guevremont, played a song hed written for the class. Now, he finds himself in the national spotlight, not as the guitarist of a rock band, but as a leading expert on a worldwide pandemic. Hes often quoted as an expert on the coronavirus, and last week he was the subject of a profile in GQ magazine.

Its one thing to be in the news and give comments about things, but its another thing to be the focus of an article in a national publication, he said.

Sheahan said he couldnt predict how the pandemic will play out, but our most powerful tool will be a vaccine to bring the situation under control. Until that time, he said, were likely to continue to see waves of social distancing measures to keep the disease in check.

Theres a ton of work that needs to be done, and everybody is just coming together to make it happen, he said.

Timothy Sheahan suits up in protective gear before working with virus specimens.

Read more:
Meet the North Smithfield native working on a cure for coronavirus - Valley Breeze

The epinephrine market in APAC is anticipated to reach US$ 953.08 million in 2027 from US$ 486.79 million in 2019 – P&T Community

NEW YORK, April 22, 2020 /PRNewswire/ --

The epinephrine market in APAC is anticipated to reach US$ 953.08 million in 2027 from US$ 486.79 million in 2019. The market is projected to grow at a CAGR of 8.9% during 20202027.

Read the full report: https://www.reportlinker.com/p05887329/?utm_source=PRN

The epinephrine market is growing primarily due to increasing production of generic epinephrine and cheaper epinephrine products and government regulations such as approval of generic drug alternative to epinephrine autoinjectors in APAC.Factors such lack of availability of epinephrine drug are likely to restrain the growth of the market in the coming years.

However, the increasing R&D expenditure for growing pipeline of epinephrine is expected to have a positive impact on the growth of the epinephrine market in APAC in the coming years.

Anaphylaxis is a severe, life threatening allergic reaction characterized by symptoms such as skin redness and itching, swallowing and breathing difficulties, wheezing, rapid breathing rate (tachypnoea), accelerated heart rate (tachycardia), and falling blood pressure.It may involve multiple systems of the human body.

Anaphylaxis is caused by exposure to an allergen (foods, insect stings, or medicines) that is recognized as a non-self by a human body.

The incidence of anaphylaxis is increasing; more than 1 billion people worldwide suffered from respiratory diseases in 2018asthma to which is a major contributor, according to the World Health Organization (WHO).The top 3 countries for both asthma incidence and prevalence in Asia were India, China, and Indonesia, driven largely by population size nearly half (48%) of the estimated O3 attributable, the leading cause of air pollution causing infections and allergies, and over half (56%) of hospitalizations due to asthma were recorded in Southeast Asia (including India), and Western Pacific regions (includes China).

Global burden of disease data analysis revealed more than 1 million premature deaths attributable to ambient air pollution in 2015 in India.More than 1 million additional deaths can be attributed to household air pollution.

The Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) plans to build a consortium and calls to action for the health and environmental global bodies and national authorities to address this major threat to human health.Anaphylaxis requires immediate medical treatment, and it can turn lethal if not treated properly.

Therefore, the demand for epinephrine is expected to increase during the forecast period.

In 2019, the auto-injectors segment accounted for the largest market share in the epinephrine market in Asia Pacific.Epinephrine auto-injectors are measured dosages used to treat life-threatening allergic reactions.

The epinephrine auto-injectors can be self-administered. The auto-injectors segment is also estimated to mark the highest CAGR in the market during the forecast period owing to the increasing development of this segment resulting in the growth of the market in near future.

In 2019, the anaphylaxis segment held the most significant share of the epinephrine market, by application.This segment is also anticipated to hold a considerable portion of the market by 2027 owing to the need for treatment of anaphylaxis and other allergies in people.

The segment is also anticipated to witness growth at a significant rate during the forecast period.

A few significant secondary sources for epinephrine included in the report are World Health Organization (WHO); Food and Drug Administration (FDA); Food Allergy Research & Education; Centers for Disease Control and Prevention (CDC); and Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI).

Read the full report: https://www.reportlinker.com/p05887329/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-epinephrine-market-in-apac-is-anticipated-to-reach-us-953-08-million-in-2027-from-us-486-79-million-in-2019--301045524.html

SOURCE Reportlinker

View post:
The epinephrine market in APAC is anticipated to reach US$ 953.08 million in 2027 from US$ 486.79 million in 2019 - P&T Community

Alumni Voices: The Way We Do Healthcare Will Never Be the Same – Davidson News

The amount of flexibility and innovation that has been demonstrated, the heavy workload that has been handled, reconfiguring who is working where in a health care system, Permar said, all of that has been part of a story people are not seeing.

Permar, a 1997 graduate of Davidson, is an associate dean and a professor of pediatrics and immunology at Duke University School of Medicine. She sees enormous shifts in her day-to-day experience at Dukes hospital, and in her broader research and teaching. Hospital staff are using safer channels for talking to patients, call it medical distancing, such as calling a phone in the patients room to ask questions and gather information. Doctors and nurses are seeing patients over video connections to help prevent the spread of the virus.

For as long as Ive been in medicine we have been talking about telehealth, Permar said, and we implemented it in a week.

Dukes hospital is screening everyone who enters. A health care professional asks visitors questions about exposure to COVID-19, travel and symptoms.Temperature checks are next. The checks create lines, so staff have to shift schedules to allow time to get in. All health care staff at hospitals are wearing masks.

The money side of health care, billing, has been based on a provider seeing a patient in person. Providers were uncertain how to bill for video visits, how to handle the technology and whether patients would accept the idea, Permar said. They moved quickly past those hurdles when the pandemic settled in, she said, and will dramatically increase the use of telehealth in the years to come.

Permar predicts policy makers will be forced to confront the nations insufficient stockpiles, such as the depletion of protective gear for medical personnel.

We have reduced stockpile capacity and pandemic preparedness over time to save costs, Permar said. It didnt reduce costs in the end when we look at the hit to the economy.

When shes not working at the hospital or standing up a new program in vaccine COVID-19 research, Permar has shared observations from her work and research on social media, including this recent reflection:

We will all remember the actions we took during this pandemic, how we responded, what our children observed, and how we contributed.

Additional Media

More:
Alumni Voices: The Way We Do Healthcare Will Never Be the Same - Davidson News

Global Market for Biosimilars in Immunology: In-depth Assessment of Key Players in the Space Across the 9 Major Markets – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Biosimilars in Immunology" report has been added to ResearchAndMarkets.com's offering.

This report combines key opinion leader insight and interviews with players in the US, France, Germany, Italy, Spain, the UK, Japan, India and South Korea to provide an in-depth review of the biosimilars market for major autoimmune diseases. The report includes an assessment of ongoing clinical trials, the geographical location of trial sponsors, discussion of the key players in the medical marijuana space as well as insights from industry experts discussing market challenges and considerations of stakeholders in the arena.

Europe leads the way for immunology biosimilars in the 7MM, and India is at the forefront in the emerging markets. In terms of immunology biosimilar penetration, the 5EU and India demonstrate the highest favorability towards uptake of biosimilars.

Japan and South Korea have an intermediate biosimilar penetration index, while the US market is the least favorable towards biosimilars. Pricing is a key issue for expensive-to-develop biosimilars entering an increasingly crowded autoimmune disease market.Biosimilars are intended to relieve healthcare-associated cost burdens; however, the economic effects of incorporating them into clinical practice are unclear, due to increased time and staff costs required for switching patients onto biosimilars.

Pricing can be a differentiating strategy among different biosimilars and larger discounts over originator brands can boost greater uptake of specific biosimilars. Quotas dictate prescribing patterns in the 5EU; however, physicians show concern about switching to a biosimilar from the originator brand. The majority of KOLs interviewed by indicated that they used biosimilars mostly for new patients. KOLs also cited reluctance to switch existing patients to biosimilars, highlighting that they did not want to change a biologic treatment that was working for the patient.

Other reasons against switching included lack of incentives for physicians, lack of switching data, and placebo effects. Biogen, Sandoz, Pfizer, and Amgen are dominating the immunology biosimilars field. The immunology biosimilars space is dominated in developed markets by established brand names, including Biogen, Sandoz, Pfizer, and Amgen. In India and South Korea, major biosimilar players include Celltrion, Cipla, and Zydus Cadila.

Scope of the report:

Key report benefits:

Key Topics Covered:

1. Preface

2. Executive Summary

2.1 Key Findings

2.2 KOL and Payer Insights

3. Introduction

3.1 What Is a Biosimilar?

3.2 Timeline of Immunology Biosimilar Development

3.3 Marketed and Pipeline Immunology Biosimilars in the 9MM

4. Biosimilar Regulatory Pathways Across Geographies

4.1 Biosimilar Regulatory Pathways

4.2 US Biosimilar Regulatory Pathway

4.3 EU Biosimilar Regulatory Pathway

4.4 Japan Biosimilar Regulatory Pathway

4.5 South Korea Biosimilar Regulatory Pathway

4.6 India Biosimilar Regulatory Pathway

5. Biosimilar Country-Specific Dynamics, 9MM

5.1 Biosimilar Country-Specific Dynamics, 9MM

5.2 US Biosimilar Market Potential

5.3 5EU Biosimilar Market Potential

5.4 Japan Biosimilar Market Potential

5.5 South Korea Biosimilar Market Potential

5.6 India Biosimilar Market Potential

6. Important Indications in Immunology

6.1 Biologic Use in Immunology

6.2 Rheumatoid Arthritis

6.3 Psoriatic Arthritis

6.4 Axial Spondyloarthritis

6.5 Ulcerative Colitis

6.6 Crohn's Disease

6.7 Plaque Psoriasis

7. Major Players

7.1 Importance of Manufacturer Reputation

7.2 Sandoz

7.3 Celltrion

7.4 Amgen

7.5 Mylan and Biocon

7.6 Pfizer

7.7 Biogen

8. Biosimilars - Key Clinical and Commercial Concepts

8.1 Cost Savings and Market Access

8.2 Patient Type

8.3 Prescription Quotas

8.4 Biosimilarity and Interchangeability

8.5 Brand Preference

8.6 Extrapolation of Data

9. Opportunities for Biosimilar Manufacturers

9.1 Strategies for Increasing Uptake of Biosimilars

9.2 Differentiation by Pricing

9.3 Differentiation by Innovation

10. Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ucnl0i.

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Read more from the original source:
Global Market for Biosimilars in Immunology: In-depth Assessment of Key Players in the Space Across the 9 Major Markets - ResearchAndMarkets.com -...

Who Is Immune to the Coronavirus? – The New York Times

Among the many uncertainties that remain about Covid-19 is how the human immune system responds to infection and what that means for the spread of the disease. Immunity after any infection can range from lifelong and complete to nearly nonexistent. So far, however, only the first glimmers of data are available about immunity to SARS-CoV-2, the coronavirus that causes Covid-19.

What can scientists, and the decision makers who rely on science to inform policies, do in such a situation? The best approach is to construct a conceptual model a set of assumptions about how immunity might work based on current knowledge of the immune system and information about related viruses, and then identify how each aspect of that model might be wrong, how one would know and what the implications would be. Next, scientists should set out to work to improve this understanding with observation and experiment.

The ideal scenario once infected, a person is completely immune for life is correct for a number of infections. The Danish physician Peter Panum famously figured this out for measles when he visited the Faroe Islands (between Scotland and Iceland) during an outbreak in 1846 and found that residents over 65 who had been alive during a previous outbreak in 1781 were protected. This striking observation helped launch the fields of immunology and epidemiology and ever since, as in many other disciplines, the scientific community has learned that often things are more complicated.

One example of more complicated is immunity to coronaviruses, a large group of viruses that sometimes jump from animal hosts to humans: SARS-CoV-2 is the third major coronavirus epidemic to affect humans in recent times, after the SARS outbreak of 2002-3 and the MERS outbreak that started in 2012.

Much of our understanding of coronavirus immunity comes not from SARS or MERS, which have infected comparatively small numbers of people, but from the coronaviruses that spread every year causing respiratory infections ranging from a common cold to pneumonia. In two separate studies, researchers infected human volunteers with a seasonal coronavirus and about a year later inoculated them with the same or a similar virus to observe whether they had acquired immunity.

In the first study, researchers selected 18 volunteers who developed colds after they were inoculated or challenged, as the term goes with one strain of coronavirus in 1977 or 1978. Six of the subjects were re-challenged a year later with the same strain, and none was infected, presumably thanks to protection acquired with their immune response to the first infection. The other 12 volunteers were exposed to a slightly different strain of coronavirus a year later, and their protection to that was only partial.

In another study published in 1990, 15 volunteers were inoculated with a coronavirus; 10 were infected. Fourteen returned for another inoculation with the same strain a year later: They displayed less severe symptoms and their bodies produced less of the virus than after the initial challenge, especially those who had shown a strong immune response the first time around.

No such human-challenge experiments have been conducted to study immunity to SARS and MERS. But measurements of antibodies in the blood of people who have survived those infections suggest that these defenses persist for some time: two years for SARS, according to one study, and almost three years for MERS, according to another one. However, the neutralizing ability of these antibodies a measure of how well they inhibit virus replication was already declining during the study periods.

These studies form the basis for an educated guess at what might happen with Covid-19 patients. After being infected with SARS-CoV-2, most individuals will have an immune response, some better than others. That response, it may be assumed, will offer some protection over the medium term at least a year and then its effectiveness might decline.

Other evidence supports this model. A recent peer-reviewed study led by a team from Erasmus University, in the Netherlands, published data from 12 patients showing that they had developed antibodies after infection with SARS-CoV-2. Several of my colleagues and students and I have statistically analyzed thousands of seasonal coronavirus cases in the United States and used a mathematical model to infer that immunity over a year or so is likely for the two seasonal coronaviruses most closely related to SARS-CoV-2 an indication perhaps of how immunity to SARS-CoV-2 itself might also behave.

If it is true that infection creates immunity in most or all individuals and that the protection lasts a year or more, then the infection of increasing numbers of people in any given population will lead to the buildup of so-called herd immunity. As more and more people become immune to the virus, an infected individual has less and less chance of coming into contact with a person susceptible to infection. Eventually, herd immunity becomes pervasive enough that an infected person on average infects less than one other person; at that point, the number of cases starts to go down. If herd immunity is widespread enough, then even in the absence of measures designed to slow transmission, the virus will be contained at least until immunity wanes or enough new people susceptible to infection are born.

At the moment, cases of Covid-19 have been undercounted because of limited testing perhaps by a factor of 10 in some places, like Italy as of late last month. If the undercounting is around this level in other countries as well, then a majority of the population in much (if not all) of the world still is susceptible to infection, and herd immunity is a minor phenomenon right now. The long-term control of the virus depends on getting a majority of people to become immune, through infection and recovery or through vaccination how large a majority depends on yet other parameters of the infection that remain unknown.

One concern has to do with the possibility of reinfection. South Koreas Centers for Disease Control and Prevention recently reported that 91 patients who had been infected with SARS-CoV-2 and then tested negative for the virus later tested positive again. If some of these cases were indeed reinfections, they would cast doubt on the strength of the immunity the patients had developed.

An alternative possibility, which many scientists think is more likely, is that these patients had a false negative test in the middle of an ongoing infection, or that the infection had temporarily subsided and then re-emerged. South Koreas C.D.C. is now working to assess the merit of all these explanations. As with other diseases for which it can be difficult to distinguish a new infection from a new flare-up of an old infection like tuberculosis the issue might be resolved by comparing the viral genome sequence from the first and the second periods of infection.

For now, it is reasonable to assume that only a minority of the worlds population is immune to SARS-CoV-2, even in hard-hit areas. How could this tentative picture evolve as better data come in? Early hints suggest that it could change in either direction.

It is possible that many more cases of Covid-19 have occurred than have been reported, even after accounting for limited testing. One recent study (not yet peer-reviewed) suggests that rather than, say, 10 times the number of detected cases, the United States may really have more like 100, or even 1,000, times the official number. This estimate is an indirect inference from statistical correlations. In emergencies, such indirect assessments can be early evidence of an important finding or statistical flukes. But if this one is correct, then herd immunity to SARS-CoV-2 could be building faster than the commonly reported figures suggest.

Then again, another recent study (also not yet peer-reviewed) suggests that not every case of infection may be contributing to herd immunity. Of 175 Chinese patients with mild symptoms of Covid-19, 70 percent developed strong antibody responses, but about 25 percent developed a low response and about 5 percent developed no detectable response at all. Mild illness, in other words, might not always build up protection. Similarly, it will be important to study the immune responses of people with asymptomatic cases of SARS-CoV-2 infection to determine whether symptoms, and their severity, predict whether a person becomes immune.

The balance between these uncertainties will become clearer when more serologic surveys, or blood tests for antibodies, are conducted on large numbers of people. Such studies are beginning and should show results soon. Of course, much will depend on how sensitive and specific the various tests are: how well they spot SARS-CoV-2 antibodies when those are present and if they can avoid spurious signals from antibodies to related viruses.

Even more challenging will be understanding what an immune response means for an individuals risk of getting reinfected and their contagiousness to others. Based on the volunteer experiments with seasonal coronaviruses and the antibody-persistence studies for SARS and MERS, one might expect a strong immune response to SARS-CoV-2 to protect completely against reinfection and a weaker one to protect against severe infection and so still slow the viruss spread.

But designing valid epidemiologic studies to figure all of this out is not easy many scientists, including several teams of which Im a part are working on the issue right now. One difficulty is that people with a prior infection might differ from people who havent yet been infected in many other ways that could alter their future risk of infection. Parsing the role of prior exposure from other risk factors is an example of the classic problem epidemiologists call confounding and it is made maddeningly harder today by the fast-changing conditions of the still-spreading SARS-CoV-2 pandemic.

And yet getting a handle on this fast is extremely important: not only to estimate the extent of herd immunity, but also to figure out whether some people can re-enter society safely, without becoming infected again or serving as a vector, and spreading the virus to others. Central to this effort will be figuring out how long protection lasts.

With time, other aspects of immunity will become clearer as well. Experimental and statistical evidence suggests that infection with one coronavirus can offer some degree of immunity against distinct but related coronaviruses. Whether some people are at greater or lesser risk of infection with SARS-CoV-2 because of a prior history of exposure to coronaviruses is an open question.

And then there is the question of immune enhancement: Through a variety of mechanisms, immunity to a coronavirus can in some instances exacerbate an infection rather than prevent or mitigate it. This troublesome phenomenon is best known in another group of viruses, the flaviviruses, and may explain why administering a vaccine against dengue fever, a flavivirus infection, can sometimes make the disease worse.

Such mechanisms are still being studied for coronaviruses, but concern that they might be at play is one of the obstacles that have slowed the development of experimental vaccines against SARS and MERS. Guarding against enhancement will also be one of the biggest challenges facing scientists trying to develop vaccines for Covid-19. The good news is that research on SARS and MERS has begun to clarify how enhancement works, suggesting ways around it, and an extraordinary range of efforts is underway to find a vaccine for Covid-19, using multiple approaches.

More science on almost every aspect of this new virus is needed, but in this pandemic, as with previous ones, decisions with great consequences must be made before definitive data are in. Given this urgency, the traditional scientific method formulating informed hypotheses and testing them by experiments and careful epidemiology is hyper-accelerated. Given the publics attention, that work is unusually on display. In these difficult circumstances, I can only hope that this article will seem out of date very shortly as much more is soon discovered about the coronavirus than is known right now.

Marc Lipsitch (@mlipsitch) is a professor in the Departments of Epidemiology and Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health, where he also directs the Center for Communicable Disease Dynamics.

Read the original here:
Who Is Immune to the Coronavirus? - The New York Times

Monitoring the immune system to fight COVID-19: CD4 status, lymphopenia, and infectivity – Science Magazine

30 April 2020

12:00 p.m. ET

Register now!

Andrea Cossarizza, M.D., Ph.D.

University of Modena and Reggio Emilia School of MedicineModena, Italy

Maurice OGorman, Ph.D., M.B.A., (D)ABMLI

Children's Hospital Los Angeles,Los Angeles, CA

Lishomwa (Lish) Ndhlovu, M.D., Ph.D.

Weill Cornell MedicineNew York, NY

Sean Sanders, Ph.D.

Science/AAASWashington, DC

The COVID-19 pandemic has struck the global population with unparalleled speed and ferocity. Researchers around the world are scrambling to learn about the biology, pathology, and genetics of SARS-CoV-2the novel coronavirus responsible for COVID-19while clinicians are seeking treatments, old and new, that might slow its infectivity and deadliness. In this webinar, we will explore what scientists are learning by using flow cytometry to study patients with COVID-19 in order to elucidate risk and disease severity. These experts are global leaders in cytometry and infectious disease, working on the frontlines of the COVID-19 outbreaks. They will provide concrete examples of how flow cytometry has been harnessed to provide key laboratory evidence that can be used in the fight against SARS-CoV-2 and COVID-19. Viewers will have the opportunity to put their questions to the expert panel during the live broadcast.

During the webinar, attendees will:

This webinar will last for approximately 60 minutes.

University of Modena and Reggio Emilia School of MedicineModena, Italy

Dr. Cossarizza completed his M.D. degree at the University of Padova in Italy before receiving a Ph.D. in oncology from the University of Modena and Reggio Emilia (UNIMORE) and the University of Bologna, also in Italy. After specializing in clinical pathology at UNIMORE, he obtained an associate professorship there. In 2005, he was appointed a professor in the international Ph.D. program at the University of Valencia in Spain, where he later became a research professor. In 2010, he became a full professor in pathology and immunology in the Faculty of Medicine at UNIMORE. He is a member of several editorial boards of international journals, and in 2016 was elected president of the International Society for Advancement of Cytometry. His primary research focus is identifying the molecular and cellular basis for the involvement of the immune system in diseases and infections, including HIV/AIDS and sepsis, as well as its role in pathophysiological conditions related to aging and neurodegeneration. Dr. Cossarizza has notable experience in the development and use of new flow cytometry approaches in immunological research.

Children's Hospital Los Angeles,Los Angeles, CA

Dr. OGorman earned his Masters and Ph.D. at the University of British Columbia before completing a postdoctoral fellowship at the University of North Carolina at Chapel Hill. He then joined the faculty at the Feinberg School of Medicine at Northwestern University, during which time he earned his MBA from Northwestern and served as vice chair of Pathology and Laboratory Medicine and director of Diagnostic Immunology and Flow Cytometry at Childrens Memorial Hospital in Chicago. He is currently chief of laboratory medicine, as well as director of the Clinical Lab and the Diagnostic Immunology and Flow Cytometry Laboratory at Childrens Hospital Los Angeles, and a professor of pathology and pediatrics at the Keck School of Medicine of the University of Southern California. Dr. OGormans research interests include immunopathogenesis of immune systemrelated disorders, investigation of immune mechanisms of immune suppression withdrawal in liver transplant patients, and the development of novel immune-related diagnostic laboratory tests. Additionally, he provides ad hoc reviews for multiple journals, including Cytometry,Journal of Leukocyte Biology, Journal of Immunological Methods, Clinical and Diagnostic Laboratory Immunology, and Archives of Pathology & Laboratory Medicine.

Weill Cornell MedicineNew York, NY

Dr. Ndhlovu is a professor of immunology at Weill Cornell Medicine in New York and principal investigator of the HIV and Emerging Pathogens Immunopathogenesis Laboratory in the Division of Infectious Diseases, also at Weill Cornell. A translational immunologist, he leads a research team dedicated to confronting the challenges of HIV and aging, with an emphasis on limiting disease complications and developing curative strategies. His program is now bringing the same urgency and focus to the COVID-19 pandemic, using both single-cell and epigenetic approaches to resolve molecular mechanisms regulating viral entry of SARS-CoV-2 infection across different tissues and cell types. His work seeks to identify therapeutic host targets and future therapies that reduce morbidity and mortality, and relieve the burden of this disease on society. Dr. Ndhlovu completed his undergraduate degree at the University of Zambia, his medical training at the University of Zambia Medical School, and his doctorate at Tohoku University School of Medicine in Japan.

Science/AAASWashington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Go here to read the rest:
Monitoring the immune system to fight COVID-19: CD4 status, lymphopenia, and infectivity - Science Magazine

Why we need more than just scientists to document the pandemic – RTE.ie

Opinion: we need to recognise that thiscrisis is as much about society and politicsas it is about virology, immunology and economics

Remarkable efforts have been made by a host of researchers in Ireland to address the Covid-19 crisis. These rangefrom studies in immunology to symptom-tracking technology, development of reagents for testingand a number of engineering solutions to address the need for ventilators and other essential equipment. The urgency and importance of this work is unquestionable and theimmediate requirement of reducing the death toll and the demands on hospitals remain of utmost importance. All of us will benefit from breakthroughs and successes as research continues.

But if we are to rise to the challenge presented by coronavirus, we must recognise that science and healthcare represent only one part of the equation. The rest of the story is essentially social, political and economic. In this trio of concerns, economic issues will dominate discussion as we attempt to navigate through a huge contraction of the economy, attended by massive job losses, business closures, and a remarkable strain on fiscal resources during a severe global downturn. Fortunately, institutions like the Central Bank and government departments have the resources of the ESRIto draw on foracademic expertise.

The risk is that in the midst of these demands and discussions we neglect the urgent responsibility to understand the social and political conditions underpinning the unfolding crisis. Only by coming to terms with these questions can we hope to avoid future calamities on this scale. The search for a vaccine constitutes a crucial remedy, but it will not in itself identify strengths and weaknesses in how governments have responded and how societies mobilise to confront a pandemic.

From RT Radio 1's The Business, a look at how the searchto find a coronavirus vaccine is progressing withFionnuala Keane (Health Research Board) and Dr Philip Cruz (Glaxo Smith Kline)

To date, major funding calls in Ireland have emerged from the Health Research Board in partnership with the Irish Research Council and Science Foundation Ireland. Some welcome scope existed in the former's call for "social and policy countermeasures", but we clearly need a much more wide-open approach that invites investigation of a series of complex, interrelated phenomena. Here is a list to be getting on with.

We have rich comparative information to harvest in comparing how different political systems have confronted the crisis. Techniques adopted in China to fight the virus, where it broke out, relied on an authoritarian government, even as that very system and lack of open reporting encouraged local officials not to indicate the gravity of the threat to public health. The lack of openness in Iran also deepened the disaster there.

South Korea, Taiwan and Germany have had success in mitigating the outbreakwith different models. In Europe, the Netherlands and Sweden have taken very different approaches by thus far refusing major lockdowns. We will need to examine and understandthe strength and weakness of their methods and how their social expectations and compliance have been managed.

From RT News, a report on mass burials in New York Cityamid record Covid-19 death rate

The staggering example of political dysfunction is the United States, now the world leader in terms of confirmed cases and the number of deaths. The Trump administration's undermining of agencies and departments, the lack of co-ordination between the states and the federal government, and opposition to healthcare reform have all played a part. Understanding these problems is vital because the countrys capacity to recover will determine the economic fate of many parts of the world.

In Ireland, the acute consequences of having two jurisdictions on the island have presented new challenges to co-operation and consistency. We have much to consider in how we coordinate our activities going forward since the virus is no respecter of Brexit and the border.

Public understanding of the Covid-19 crisis requires news media and reliable outlets for information. But this is the first pandemic in the era of social media, a wellspring of misinformation, rumour and supposed cures. The decisive role of trust and expertise demands renewed attention, even as crippling political attacks and polarisation have occurred, notably in the US. At the same time, the harvesting of data and systems of surveillance calls for much greater ethical reflection and assessment.

FromRT Radio 1'sDrivetime,Della Kilroy reports on how domestic abuse shelters are coping with social distancing restrictions

Social issues that come into play include not only the logistics of achieving isolation, but also the uneven effects of the lockdown. This is seen in differences in physical space, resources (such asinternet access and computer equipment) family structures (divorce and separation, people living alone etc), provisions for care, and the organisation of domestic space, not least to facilitate home schooling.

Social attitudes to ageing have taken on new significance as well as views about those occupying the frontline, not just in hospitals but in stores and delivery services - many of them in low paid positions. The arts have taken a backseat, by and large, but how have people accessed culture in the time of crisis and, perhaps more importantly, why do they continue to do so? More generally, what is the experience of virtualisation and its impact on work and social life? How can we write the history of the current response and how does it compareto past pandemics?

As the health crisis unfolds around the world, hard truths once again surface about the realities of our relationship with what is termed the Global South. When the disease escalates in Africa, what will be the response? Donald Trump's politically motivated halt on funding the WHO will have serious repercussions in this context.

From RT News, a report on the global condemnation of US president Donald Trump's decision to stop funding the WHO

Some attention has been given to the fate of those living in crowded migrant camps, and in direct provision centres in Ireland, but we have a new opportunity to study the effects of inequality, migration, and resources. We are simply lucky that Covid-19 is not as virulent as Ebola (which has an average rate of fatality of 50%). If coronavirus claimed lives at that rate, the losses inflicted by it would be extraordinary. Arguably, we failed to act to set proper systems in place because Ebola was largely confined to Africa. New lessons in racism abound at this time.

We all hope that a vaccine will be devised as soon as possible. Immunology, virology, and epidemiology are at the forefront of efforts. But if we don't get on top of the political and social challenges, we will be right back where we started the next time a crisis of this kind happens. Funding research is the first step in what needs to become a coordinated effortacross all the disciplines. Ireland can take the lead and show just how much this shared effort matters.

The views expressed here are those of the author and do not represent or reflect the views of RT

Read this article:
Why we need more than just scientists to document the pandemic - RTE.ie

Researcher aims to promote diversity as member of global academy – UM Today

April 21, 2020

A UM faculty member who studies immune cells in her lab and promotes diversity in science has been selected for membership in a prestigious worldwide organization.

Dr. Janilyn Arsenio, assistant professor of internal medicine and immunology in the Max Rady College of Medicine, has been honoured with admission to the Global Young Academy (GYA).

Arsenio holds a Canada Research Chair in systems biology of chronic inflammation. She is one of four Canadians among this years 40 GYA inductees, who represent 30 countries.

The GYA brings together outstanding early-career researchers for international dialogue and collaboration. Members, who are typically in their 30s, are selected for their scientific excellence and commitment to service. Each member joins the academy for a term of five years.

The academy undertakes projects in a number of areas, from promoting science education and outreach to improving the research environment.

Its a group of young scientists who share a motivation to improve the scientific culture, Arsenio says. I applied because Im really passionate about promoting equity, diversity and inclusion in science.

As a visible minority academic woman in science, I feel a personal responsibility to advocate for that. Im a member of Canadian and American organizations like the Society for Canadian Women in Science and Technology and the Association for Women in Science, and this is an opportunity to interact on a more international level.

The Winnipeg-born Arsenio, who is of Filipino heritage, earned her bachelors degree in microbiology and her PhD in medical microbiology and infectious diseases at UM. She did four years of postdoctoral research, primarily in immunology, at the University of California San Diego before joining the UM faculty in 2017.

While in California, she learned techniques for analyzing the genetic material of individual cells. She brought that expertise to her lab at UMs Manitoba Centre for Proteomics and Systems Biology, making it the first lab in the province to enter the field of single-cell genomics.

Arsenio studies, at the molecular level, how immune cells behave in response to infection, chronic inflammation and disease. Were trying to understand how cells change to become functional protectors of the immune system, versus how their functions are lost during disease, she says.

The professor is vice-chair of Women in Science: Development, Outreach and Mentoring (WISDOM), a Manitoba organization based in the Rady Faculty of Health Sciences that works to address the under-representation of women in science, particularly in leadership. She also serves on the equity, diversity and inclusion committee of the Rady Faculty.

Arsenios previous honours include the American Association of Immunologists Young Investigator Award, which she received in 2016.

Her formal induction into the Global Young Academy was to have been at the academys 2020 conference and annual general meeting in India this June. Because of the COVID-19 crisis, the gathering has been converted to an e-conference. Hopefully, the new members will interact online, and we can meet in person at the 2021 meeting in Japan, Arsenio says.

Although she has studied infectious diseases, the scientist says its surreal to experience an outbreak on the scale of COVID-19. You learn about this during your training, but you never think that youll live through a pandemic, she says.

Like all lab scientists in the Rady Faculty, Arsenio has closed her lab and put her experiments on hold because of the pandemic.

Its very difficult to have to pause your research, she says. But were doing what we have to do for everyones well-being.

ALISON MAYES

Excerpt from:
Researcher aims to promote diversity as member of global academy - UM Today

Markotic: 5620 serological tests to be used as aid in diagnostics – Croatia Week

Alemka Markotic(Photo: HINA/ Dario GRZELJ/ dag)

ZAGREB, April 21 (Hina) The director of the Hospital for Infectious Diseases in Zagreb, Alemka Markotic, has said that serological test kits have been ordered and that tests will be initially carried out on medical workers to see if any of them have recovered from COVID-19 infection unknowingly.

We have also received 5,620 testkits from the national civil protection authority and will use them as aid in diagnostics. We are planning even more tests to include a greater number of people in nursing homes. We are still looking at which sections of the population will be tested, Dr Markotic said in an interview with the Vecernji List daily of Tuesday.

She noted that social groups that turned out to be more prone to infection would be tested more frequently.

She also spoke of the Institute of Immunology and whether it could makeserological test kits.

The Institute of Immunology is our strategic institution. They did not produce diagnostic tests, but vaccines. That, however, does not mean that with some changes they could not produce certain diagnostic tests as well. In fact, a reform of the Institute of Immunology would be good. This institutions has been left to decline for years and many people have left. It will take a lot of energy to build plants, Markotic said.

Read the rest here:
Markotic: 5620 serological tests to be used as aid in diagnostics - Croatia Week